Clinical Practice Guideline

Chronic Kidney Disease

Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease

(Endorsed, June 2014)

The guideline, Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease, was developed by the American College of Physicians and endorsed by the American Academy of Family Physicians.

Key Recommendations

  • Asymptomatic adults without risk factors for chronic kidney disease should not be screened for chronic kidney disease.
  • Adults who are taking an angiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker should not be tested for proteinuria, whether or not they have diabetes.
  • Adults with hypertension and stage 1 to 3 chronic kidney disease should be treated with either an angiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker.
  • Adults with stage 1 to 3 chronic kidney disease and elevated low-density lipoprotein should be treated with statin therapy.

Download article with full recommendation for more information on Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease.


These guidelines are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute the individual judgment brought to each clinical situation by the patient’s family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These guidelines are only one element in the complex process of improving the health of America. To be effective, the guidelines must be implemented.